Literature DB >> 29573557

The correlation between the Childhood Health Assessment Questionnaire and disease activity in juvenile idiopathic arthritis.

Watchareewan Sontichai1,2, Soamarat Vilaiyuk1.   

Abstract

BACKGROUND: The Childhood Health Assessment Questionnaire (CHAQ) has been adapted from the Stanford Health Assessment Questionnaire for assessing functional ability in children. The present study aimed to determine the correlation between CHAQ and disease activity in juvenile idiopathic arthritis (JIA) during active and inactive disease.
METHODS: JIA patients in the Pediatric Department, Ramathibodi Hospital, between January 2011 and December 2013, were included in the study. The CHAQ disability index (DI) and disease activity variables, including active and limited joint count, erythrocyte sedimentation rate, patient's global assessment (PtGA), physician's global assessment (PGA) and 27-joint Juvenile Arthritis Disease Activity Score (JADAS27), were collected from medical records for each patient over six visits. At each visit, each patient was classified as having either active or inactive disease. The correlations between CHAQ-DI and disease activity variables were analysed using Spearman's correlation.
RESULTS: The classification of 139 JIA patients consisted of enthesitis-related arthritis (30.9%), systemic JIA (28.1%), oligoarthritis (16.5%), rheumatoid factor (RF)-negative polyarthritis (15.1%), RF-positive polyarthritis (6.5%) and undifferentiated arthritis (2.9%). Out of 812 patient visits, 606 were in active disease and 206 were in inactive disease. RF-negative polyarthritis had the highest CHAQ-DI (0.39 ± 0.66), while oligoarthritis had the lowest (0.20 ± 0.32). There was a good correlation between CHAQ-DI and JADAS27, PGA and PtGA in all JIA subtypes (p < 0.05) during active disease, but a poor correlation between CHAQ-DI and disease activity variables during inactive disease.
CONCLUSIONS: CHAQ-DI had a good correlation with disease activity during active disease but a poor correlation during inactive disease. Therefore, CHAQ is only useful for assessing functional ability during active disease.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  arthritis; functional assessment; questionnaire

Mesh:

Year:  2018        PMID: 29573557     DOI: 10.1002/msc.1239

Source DB:  PubMed          Journal:  Musculoskeletal Care        ISSN: 1478-2189


  5 in total

1.  Number of Episodes Can Be Used as a Disease Activity Measure in Familial Mediterranean Fever.

Authors:  David Piskin; Zehra Serap Arici; Dilek Konukbay; Micol Romano; Balahan Makay; Nuray Ayaz; Yelda Bilginer; Roberta A Berard; Hakan Poyrazoglu; Ozgur Kasapcopur; Ronald M Laxer; Kathy Speechley; Erkan Demirkaya
Journal:  Front Pediatr       Date:  2022-04-27       Impact factor: 3.569

2.  Utilizing ultrasound findings of a single indicator joint to assess non-systemic juvenile idiopathic arthritis.

Authors:  Yung-Hsien Huang; Ya-Chiao Hu; Chun-Hua Liao; Bor-Luen Chiang; Cheng-Hsun Lu; Ko-Jen Li; Yao-Hsu Yang
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-29       Impact factor: 3.054

Review 3.  Enthesitis-related arthritis: monitoring and specific tools.

Authors:  Hanène Lassoued Ferjani; Kaouther Maatallah; Sirine Miri; Wafa Triki; Dorra Ben Nessib; Dhia Kaffel; Wafa Hamdi
Journal:  J Pediatr (Rio J)       Date:  2021-09-28       Impact factor: 2.990

4.  The value of the patient global health assessment in polyarticular juvenile idiopathic arthritis: a nested cohort study.

Authors:  Rebecca Trachtman; Rula Issa; Stephanie Pan; Karen M Wilson; Daniel J Lovell; Karen B Onel
Journal:  J Patient Rep Outcomes       Date:  2021-06-26

5.  Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.

Authors:  Nitichen Kittiratchakool; Disorn Kulpokin; Chonticha Chanjam; Soamarat Vilaiyuk; Sirirat Charuvanij; Gun Phongsamart; Parichat Khaosut; Manasita Tanya; Ratanavadee Nanagara; Sira Nantapaisarn; Pattara Leelahavarong
Journal:  BMJ Open       Date:  2020-09-15       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.